Alnylam Inks Deal With Anti-infective Specialist Cubist To Develop RSV Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Respiratory syncytial virus program brought in $35 million upfront from Cubist and an earlier Japanese deal with Kyowa Hakko.
You may also be interested in...
Alnylam’s Liver Cancer RNAi Program Enters the Clinic
RNAi leader advances its first systemically delivered program—a liposomal formulation of two siRNA molecules—into the clinic.
Alnylam’s Liver Cancer RNAi Program Enters the Clinic
RNAi leader advances its first systemically delivered program—a liposomal formulation of two siRNA molecules—into the clinic.
Alnylam's Liver Cancer RNAi Program Enters The Clinic
Alnylam Pharmaceuticals's ALN-VSP RNA interference program has begun clinical trials in patients with advanced liver cancers, the Cambridge-MA.-based biotech said April 3